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Background: The different expression level of Dickkopf-1 (DKK-1) in different cancers shows that the function of
DKK-1 depends on the histological type of the cancer cells and the tissue microenvironment. To our knowledge,
the serum expression level of DKK-1 in breast cancer is little known.
Methods: Blood samples from 125 consecutive patients diagnosed with breast cancer and 53 control subjects from
March 2008 to August 2013 were investigated. Serum DKK-1 expression levels were measured by enzyme-linked
immunosorbent assay (ELISA). The overall survival (OS) and relapse-free survival (RFS) analyzed by log-rank test, and
survival curves were plotted according to Kaplan–Meier.
Results: The mean serum level of DKK-1 in patients with breast cancer was 4.99 ± 1.50 ng/mL, and was significantly
higher than that in healthy individuals (1.88 ± 0.81 ng/mL, P < 0.001). DKK-1 level correlated significantly with TNM
stage (P = 0.009), tumor grade (P = 0.02), lymph node metastasis (P = 0.001), and expression of HER2 (P = 0.002). The
DKK-1 expression level was classified as high or low in relation to the median value, and patients with breast cancer
(n = 125) were divided into a high expression group (n = 63) and a low expression group (n = 62). The Kaplan-Meier
method for survival analysis showed that the patients with a high serum DKK-1 level had a poorer OS (48.7% vs.
81.3%, p = 0.01) and RFS (24.3% vs. 71.6%, p = 0.003) than those with a low expression level. The multivariate Cox
regression analysis indicated that serum DKK-1 level was independent prognostic factors for OS and RFS.
Conclusions: Serum DKK-1 level can be used as a noninvasive biomarker for the prognosis of breast cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_161
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Breast cancer is the most common malignancy and is
the leading cause of cancer death in females worldwide,
accounting for 23% of the total cancer cases and 14% of
the total cancer deaths [1]. Invasion and metastasis are
the major features of malignant tumors and result in poor
prognosis of patients. The invasive abilities of cancer cells
are the critical parameters of the metastatic cascade [2].
Therefore, better understanding of the prognosis and me-
tastasis associated factors and the underlying mechanisms
would help to improve patients’ prognosis. Although some
pathological factors, including estrogen receptor (ER),
progesterone receptor (PR) and c-erbB-2 (HER2), have* Correspondence: weihai_wangziliang@126.com
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unless otherwise stated.been widely used as a reference in clinical diagnosis
and treatment, their prognostic value for breast cancer
still has certain limitations. Therefore, it is important
to identify reliable prognostic markers in clinical prac-
tice for the treatment of breast cancer [3-5].
Dickkopf-1 (DKK-1), a secreted protein, is known as a
negative regulator of the Wnt signaling pathway [6].
DKK-1 binds to lipoprotein receptor-related protein-5/6
(LRP5/6) and blocks interaction with Wnt-1, resulting in
β-catenin degradation and retardation of proliferation
[7-9]. The expression and roles of DKK-1 are different
in various cancers, current studies have reported that
overexpression of DKK-1 is found in many malignant
tumors, including lung cancer, esophageal carcinomas, cer-
vical cancer, and hepatocellular carcinoma (HCC), indicating
a potential oncogenic function of DKK-1 [10-13]. However,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 DKK-1 levels in serum of breast cancer and healthy
individuals. The mean serum level of DKK-1 in patients with breast
cancer was 4.99 ± 1.50 ng/mL, and was significantly higher than that
in healthy individuals (1.88 ± 0.81 ng/mL, p < 0.001).
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significantly in human colon cancer, gastric cancer and mel-
anoma [14-16], suggesting that the function of DKK-1 may
be different in different types of cancers. In spite of these
studies, there little has been reported on the signifi-
cance of DKK-1 expression in breast cancer progres-
sion and prognosis.
In the present study, serum expression level of DKK-1 of
125 patients diagnosed with breast cancer was examined
using enzyme-linked immunosorbent assay (ELISA), and
the correlations between serum DKK-1 expression and
clinicapathological factors were explored. Furthermore, the
prognostic role of DKK-1 in breast cancer was evaluated
using Cox regression and Kaplan-Meier analysis.
Methods
Patient, and blood samples
Blood samples from 125 consecutive patients diagnosed
with breast cancer who underwent surgery at the De-
partment of Breast and Thyroid Surgery, Weihai Muni-
cipal Hospital from March 2008 to August 2013 were
investigated. 53 control subjects were randomly selected
among individuals receiving health examinations at the
Health Examination Center of Weihai Municipal Hos-
pital, any of these subjects who had a history of cancer
were excluded from the study. Blood samples were col-
lected from the patients at the time of diagnosis, before
surgery. The demographic and pathological data, includ-
ing age, gender, and the tumor stage, were obtained by a
review of the patients’ medical records. The protocol for
this study was approved by the ethics committee of Wei-
hai Municipal Hospital, and written informed consent
was obtained from each participant. A structured ques-
tionnaire was administered by well-trained interviewers
to collect information on demographic and anthropo-
metric characteristics of the enrolled subjects. Venous
blood samples were collected into anticoagulant-free
tubes and centrifuged to obtain serum samples, which
were stored at −80°C until they were assayed.
Enzyme-linked immunosorbent assay
Serum DKK-1 expression levels were measured by enzyme-
linked immunosorbent assay (ELISA) with immunoassay
kit (Miltenyi, Germany) according to the manufacturer’s di-
rections. The optical density (OD) at 450 nm was deter-
mined. The standard curves were established with OD450
as Y axle and the concentration of standard substance as X
axle. The level of protein was obtained through standard
curve. Results are reported as concentration of DKK-1 ng/
ml in samples.
Statistical analysis
Numerical variables were recorded as means ± SD and
analyzed by independent t-tests. Categorical variableswere presented as rates and analyzed by using the
chi-square test or Fisher’s exact test. The relapse-free
survival (RFS) was defined as the interval between the
operation and the date that tumor recurrence or me-
tastasis were diagnosed. Overall survival (OS) was de-
fined as the interval between the operation and the
date of death of the patient. The OS and RFS analyzed
by log-rank test, and survival curves were plotted ac-
cording to Kaplan–Meier. Univariate Cox regression
was performed on each clinical covariate to examine
its influence on patient survival. Final multivariate
models were based on step-wise addition. P-values <0.05
were considered as statistically significant. Statistical ana-
lyses were performed using SPSS 13.0 soft-ware (Chicago,
Ill., USA) and GraphPad Prism 5 (GraphPad Software
Inc., CA, USA).
Results
DKK-1 levels in serum of breast cancer
The DKK-1 levels in serum from patients with breast
cancer (n = 125), and from healthy individuals (n = 53)
were detected by ELISA. The mean serum level of DKK-
1 in patients with breast cancer was 4.99 ± 1.50 ng/mL,
and was significantly higher than that in healthy individ-
uals (1.88 ± 0.81 ng/mL, P < 0.001, shown in Figure 1).
Serum DKK-1 levels and clinicopathological characteristics
The DKK-1 expression level was classified as high or low
in relation to the median value, and patients with breast
cancer (n = 125) were divided into a high expression
group (n = 63) and a low expression group (n = 62). The
relationships between serum DKK-1 levels and clinico-
pathological characteristics of patients with breast can-
cer were analyzed (shown in Table 1). Serum DKK-1 levels
correlated significantly with TNM stage (P = 0.009), tumor
grade (P = 0.02), lymph node metastasis (P = 0.001), and
Table 1 The serum levels of DKK-1 according to
clinicopathologic characteristics of patients with
breast cancer
DKK-1 expression
Variables Cases (n) High Low p value
Age (years)
<50 59 27 32 0.61
≥ 50 66 36 30
TNM stage
I + II 71 26 45 0.009*
III 54 37 17
Grade
G1-G2 67 24 43 0.02*
G3 58 39 19
Histological type
Ductal 88 49 39 0.11
Others 37 14 23
Lymph node metastasis
Yes 46 36 10 0.001*
No 79 27 52
ER
Negative 59 33 26 0.09
Positive 66 30 36
PR
Negative 68 37 31 0.12
Positive 57 26 31
HER2
Negative 36 29 7 0.002*
Positive 89 34 55
Family history of breast cancer
Yes 73 41 32 0.07
No 52 22 30
Radiation therapy
Yes 34 19 15 0.39
No 91 44 47
Chemotherapy
Yes 46 22 24 0.31
No 79 41 38
Menopausal status
Yes 48 23 25 0.45
No 77 40 37
*Statistically significant.
ER = estrogen receptor; PR = progesterone receptor; HER-2 = c-erb B-2.
Figure 2 Survival analysis of the serum DKK-1 levels with
overall (A) and relapse-free survival (B) of patients with
breast cancer after surgery.
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correlation of serum DKK-1 levels with age (P = 0.61),
histological type (P = 0.11), expression of ER (P = 0.09),
expression of PR (P = 0.12), family history of breastcancer (P = 0.07), radiation therapy (P = 0.39), chemo-
therapy (P = 0.31), and menopausal status (P = 0.45).
Correlation of serum DKK-1 levels with OS and RFS
Considering that serum DKK-1 levels were significantly
correlated with TNM stage, tumor grade, and lymph
node metastasis, we hypothesized that serum DKK-1
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To confirm this possibility, the DKK-1 expression levels
and the prognosis of patients with breast cancer were ana-
lyzed by using the Kaplan–Meier method. The Kaplan-
Meier method for survival analysis showed that the pa-
tients with a high serum DKK-1 level had a poorer OS
(48.7% vs. 81.3%, P = 0.01; Figure 2A) and RFS (24.3% vs.
71.6%, P = 0.003; Figure 2B) than those with a low expres-
sion level. The multivariate Cox regression analysis indi-
cated that serum DKK-1 level (HR = 2.19; P = 0.002),
TNM stage (HR = 4.24; P = 0.01), and lymph node metas-
tasis (HR = 3.12; P = 0.007) were independent prognostic
factors for OS, while serum DKK-1 level (HR = 3.97;
P < 0.001), tumor grade (HR = 2.98; P = 0.009), and ex-
pression of HER2 (HR = 2.29; P = 0.02) were independent
prognostic factors for RFS (shown in Table 2).
Discussion
Over the past few years, an increasing number of studies
have focused on exploring the risk factors of breast can-
cer in order to prevent it. Up to now, many molecular
markers have been used for prognosis of breast cancer
patients, including Ki-67, Bcl-2, HER-2, ER, PR, P53,
PAR1, and FGFR1 [17-21]. These markers are all corre-
lated with patient outcomes. However, the biological po-
tential of breast cancer is difficult to predict completely
with the use of current standard risk factors. Therefore,
more persuasive prognostic indicators should be ex-
plored for the comprehensive evaluation of breast cancer
patients.
DKK-1, DKK-2, DKK-3, and DKK-4, together with a
special DKK-3 related protein termed Soggy (Sgy), com-
pose a family of DKK-related genes. DKK-1, DKK-2,
DKK-3, and DKK-4 contain 2 discrete cysteine-rich do-
mains, in which the positions of 10 cysteine residues are
supremely conserved among family members. DKK-1
and DKK-4, but not DKK-2, DKK-3 or Sgy, have been
shown to suppress the Wnt-induced secondary axisTable 2 Multivariate analyses for relapse-free survival and ov
Relapse-free survival
Variable Hazard ratio 95% CI
Age 1.06 0.23-2.35
TNM stage 3.29 0.89-7.23
Tumor grade 2.98 1.29-6.77
Histological type 0.81 0.27-3.23




DKK-1 expression 3.97 1.82-10.99
*Statistically significant.
ER = estrogen receptor; PR = progesterone receptor; HER-2 = c-erb B-2.induction in Xenopus embryos [22,23]. DKK-4 was
found to show high specificity for gastric cancer [24].
DKK-1, which was involved in some aspects of embryonic
development, was detected in mature human tissues,
mainly in the placenta. Specifically, Wnt-1 protein binds
to the frizzled receptor and the low-density lipoprotein
receptor-related protein-5/6, triggering signals important
for proliferation via β-catenin. DKK-1 binds to low-
density lipoprotein receptor-related protein-5/6 and
blocks interaction with Wnt-1 resulting in β-catenin
degradation and effects on proliferation [25]. Other re-
sult showed that DKK-1 functioned not only as an an-
tagonist of the Wnt/β-catenin pathway but also as an
agent that could up-regulate other Wnt signaling path-
ways if the requisite Wnt/receptor combinations were
available. DKK-1 also can suppress cell growth and in-
duces apoptotic cell death by activating the c-Jun N-
terminal kinase pathway [26]. The expression and roles
of DKK-1 are different in various cancers, current studies
have reported that overexpression of DKK-1 is found in
many malignant tumors, including lung cancer, esopha-
geal carcinomas, cervical cancer, and HCC, indicating a
potential oncogenic function of DKK-1 [10-13]. However,
paradoxically, the expression of DKK-1 was down-
regulated significantly in human colon cancer, gastric
cancer and melanoma [14-16]. Therefore, the different
function of DKK-1 in different cancer types depends
on the histological type of the cancer cells and the tis-
sue microenvironment. However, to our knowledge the
expression of DKK-1 in breast cancer is little known.
In the present study we investigated the expression of
DKK-1 in patients’ serum to establish if DKK-1 can be
used as a novel prognostic biomarker in human breast
cancer. In this study, we had three findings. Firstly, the
serum levels of DKK-1 in patients with breast cancer
was significantly higher than that in healthy individ-
uals, and high serum levels of DKK-1 was found to sig-
nificantly correlate with TNM stage, tumor grade,erall survival by Cox regression model
Overall survival
P-value Hazard ratio 95% CI P-value
0.57 1.21 0.35-1.30 0.23
0.06 4.24 3.21-9.22 0.01*
0.009* 3.83 0.87-4.91 0.08
0.62 0.91 0.37-1.29 0.36
0.07 3.12 2.46-10.92 0.007*
0.29 1.81 0.23-3.11 0.63
0.32 1.34 0.38-3.10 0.29
0.02* 2.12 0.91-3.91 0.06
<0.001* 2.19 1.28-9.24 0.002*
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Kaplan–Meier analysis showed that breast cancer patients
with high serum DKK-1 expression level had distinctly
shorter overall survival and relapse-free survival. Thirdly,
univariate and multivariate analyses showed that the serum
DKK-1 level was independent prognostic parameter of
overall survival and relapse-free survival in breast cancer
patients. All the results suggested that serum DKK-1 level
was befitting to predict prognosis of breast cancer patients
after surgery.
Conclusions
In conclusion, our results indicated that serum DKK-1
was overexpressed in breast cancer and high expression
of DKK-1 was associated with poor prognosis. The data
suggest that serum DKK-1 may be a useful molecular
marker in breast cancer.
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